ArcScan, Inc. Signs Definitive Agreement for $11.15 Million Preferred Series B Investment with Shanghai Haohai Biological Technology Ltd.

GOLDEN, Colo., July 21, 2021 /PRNewswire/ — ArcScan, Inc., the developer of state-of-the-art ophthalmic ultrasound imaging device “ArcScan Insight® 100, ” headquartered in Golden, Colorado, announces the execution of a Stock Purchase Agreement with Shanghai…

Click here to view the original article.